6 results on '"Merino, Jose L."'
Search Results
2. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.
- Author
-
Anker SD, Usman MS, Anker MS, Butler J, Böhm M, Abraham WT, Adamo M, Chopra VK, Cicoira M, Cosentino F, Filippatos G, Jankowska EA, Lund LH, Moura B, Mullens W, Pieske B, Ponikowski P, Gonzalez-Juanatey JR, Rakisheva A, Savarese G, Seferovic P, Teerlink JR, Tschöpe C, Volterrani M, von Haehling S, Zhang J, Zhang Y, Bauersachs J, Landmesser U, Zieroth S, Tsioufis K, Bayes-Genis A, Chioncel O, Andreotti F, Agabiti-Rosei E, Merino JL, Metra M, Coats AJS, and Rosano GMC
- Subjects
- Humans, Stroke Volume, Phenotype, Decision Making, Ventricular Function, Left, Heart Failure drug therapy, Hypertension drug therapy, Cardiology
- Abstract
Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous clinical syndrome affected in its development and progression by many comorbidities. The left ventricular diastolic dysfunction may be a manifestation of various combinations of cardiovascular, metabolic, pulmonary, renal, and geriatric conditions. Thus, in addition to treatment with sodium-glucose cotransporter 2 inhibitors in all patients, the most effective method of improving clinical outcomes may be therapy tailored to each patient's clinical profile. To better outline a phenotype-based approach for the treatment of HFpEF, in this joint position paper, the Heart Failure Association of the European Society of Cardiology, the European Heart Rhythm Association and the European Hypertension Society, have developed an algorithm to identify the most common HFpEF phenotypes and identify the evidence-based treatment strategy for each, while taking into account the complexities of multiple comorbidities and polypharmacy., (© 2023 European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
3. European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.
- Author
-
Aktaa S, Tzeis S, Gale CP, Ackerman MJ, Arbelo E, Behr ER, Crotti L, d'Avila A, de Chillou C, Deneke T, Figueiredo M, Friede T, Leclercq C, Merino JL, Semsarian C, Verstrael A, Zeppenfeld K, Tfelt-Hansen J, and Reichlin T
- Subjects
- Humans, Arrhythmias, Cardiac complications, Arrhythmias, Cardiac diagnosis, Arrhythmias, Cardiac therapy, Death, Sudden, Cardiac prevention & control, Quality Indicators, Health Care, Cardiology
- Abstract
To develop a suite of quality indicators (QIs) for the management of patients with ventricular arrhythmias (VA) and the prevention of sudden cardiac death (SCD). The Working Group comprised experts in heart rhythm management including Task Force members of the 2022 European Society of Cardiology (ESC) Clinical Practice Guidelines for the management of patients with VA and the prevention of SCD, members of the European Heart Rhythm Association, international experts, and a patient representative. We followed the ESC methodology for QI development, which involves (i) the identification of the key domains of care for the management of patients with VA and the prevention of SCD by constructing a conceptual framework of care, (ii) the development of candidate QIs by conducting a systematic review of the literature, (iii) the selection of the final set of QIs using a modified-Delphi method, and (iv) the evaluation of the feasibility of the developed QIs. We identified eight domains of care for the management of patients with VA and the prevention of SCD: (i) structural framework, (ii) screening and diagnosis, (iii) risk stratification, (iv) patient education and lifestyle modification, (v) pharmacological treatment, (vi) device therapy, (vii) catheter ablation, and (viii) outcomes, which included 17 main and 4 secondary QIs across these domains. Following a standardized methodology, we developed 21 QIs for the management of patients with VA and the prevention of SCD. The implementation of these QIs will improve the care and outcomes of patients with VA and contribute to the prevention of SCD., Competing Interests: Conflict of interest: M.J.A. is a consultant for Abbott, Boston Scientific, Bristol Myers Squibb, Daichii Sankyo, Invitae, LQT Therapeutics, and Medtronic. M.J.A. and/or Mayo Clinic are involved in an equity/intellectual property/royalty relationship with AliveCor, Anumana, ARMGO Pharma, Pfizer, and UpToDate. However, none of these entities were involved in this study. T.D. receives from InHeart—Speaker honoraria, personal (< 5.000€), Siemens—Speaker Honoraria, institutional (< 5.000€), Biotronik—Educational Course Director, personal (< 10.000€), Abbott—Speaker honoraria, personal (< 5.000€) and Boston Scientific—Adverse events committee, personal (< 5.000€). CPG Chair of the Data Science Group of EuroHeart, Deputy Editor of EHJ Quality of Care and Clinical Outcomes. Unrelated to the present work: Research grants from Abbott, BMS, BHF, Horizon 2020, NIHR; speaker’s honoraria from AstraZeneca, Raisio Group, Wondr Medical; Consulting from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Ely-Lilly, Menarini, Vifor outside the submitted work., (© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
4. Core curriculum for the heart rhythm specialist.
- Author
-
Merino JL, Arribas F, Botto GL, Huikuri H, Kraemer LI, Linde C, Morgan JM, Schalij M, Simantirakis E, Wolpert C, Villard MC, Poirey J, Karaim-Fanchon S, and Deront K
- Subjects
- Curriculum, Europe, Humans, Arrhythmias, Cardiac prevention & control, Cardiac Pacing, Artificial, Cardiology education, Catheter Ablation, Internship and Residency organization & administration
- Abstract
Heart rhythm (HR) management is rapidly developing as a subspecialty within cardiology and it is imperative to promote and ensure sufficient and homogeneous training and qualification among professionals in Europe. This encouraged the European Society of Cardiology, through the European Heart Rhythm Association (EHRA), to organize a European Core Curriculum for the HR specialist through the following: definition of the scope of the HR speciality (Syllabus), development of minimum standards and objectives for training in HR management (Curriculum), development of a model to certify HR professionals and teaching units (Accreditation), and development of a Registry for European HR accredited professionals and teaching units and their activity (Registries). The duration of the training period should be of a minimum of 2 years following general cardiology training. During this period, the trainee must develop the required knowledge, practical skills, behaviours, and attitudes to manage HR patients. The trainee must be involved in a minimum number of different procedures and achieve specified levels of competence. The training centre should be integrated within a full-service cardiology department. Assessment of the trainee and the training programmes should include reports by the training programme supervisor and the national society HR organizations, a logbook of procedures, written examinations, and assessment of professionalism. The EHRA presently requires the trainee to pass the EHRA accreditation exams (invasive EP and cardiac pacing and ICDs). Continuous learning and practice are required to maintain standards and practice because substantial changes may occur in clinical practice or the health-care environment.
- Published
- 2009
- Full Text
- View/download PDF
5. Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications
- Author
-
Rey, Juan R., Caro‐Codón, Juan, Rosillo, Sandra O., Iniesta, Ángel M., Castrejón‐Castrejón, Sergio, Marco‐Clement, Irene, Martín‐Polo, Lorena, Merino‐Argos, Carlos, Rodríguez‐Sotelo, Laura, García‐Veas, Jose M., Martínez‐Marín, Luis A., Martínez‐Cossiani, Marcel, Buño, Antonio, Gonzalez‐Valle, Luis, Herrero, Alicia, López‐Sendón, José L., Merino, José L., Merino, Jose L., Caro‐Codon, Juan, Castrejon‐Castrejon, Sergio, Iniesta, Angel M., Martinez‐Cossiani, Marcel, Merino, Carlos, Martin‐Polo, Lorena, Martinez, Luis A., Marco, Irene, Garcia‐Veas, Jose M., Rodriguez‐Sotelo, Laura, Lopez‐Sendon, Jose L., Rios, Juan Jose, Arribas, Jose R., Arnalich, Francisco, Prados, Concepción, Alvarez‐Sala, Rodolfo, Quintana, Manuel, García de Lorenzo, Abelardo, Reinoso, Francisco, Rivera, Angelica, Torres, Rosario M., Garcia‐Rodriguez, Julio, and Borobia, Alberto
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Incidence (epidemiology) ,Mortality rate ,030204 cardiovascular system & hematology ,medicine.disease ,Prevalence incidence ,03 medical and health sciences ,Drug withdrawal ,0302 clinical medicine ,Mineralocorticoid receptor ,Heart failure ,Internal medicine ,medicine ,Cardiology ,Decompensation ,Cardiology and Cardiovascular Medicine ,business - Abstract
AIMS: Data on the impact of COVID-19 in chronic heart failure (CHF) patients and its potential to trigger acute heart failure (AHF) are lacking. The aim of this work was to study characteristics, cardiovascular outcomes and mortality in patients with confirmed COVID-19 infection and a prior diagnosis of heart failure (HF). Further aims included the identification of predictors and prognostic implications for AHF decompensation during hospital admission and the determination of a potential correlation between the withdrawal of HF guideline-directed medical therapy (GDMT) and worse outcomes during hospitalization. METHODS AND RESULTS: Data for a total of 3080 consecutive patients with confirmed COVID-19 infection and follow-up of at least 30 days were analysed. Patients with a previous history of CHF (n = 152, 4.9%) were more prone to the development of AHF (11.2% vs. 2.1%; P < 0.001) and had higher levels of N-terminal pro brain natriuretic peptide. In addition, patients with previous CHF had higher mortality rates (48.7% vs. 19.0%; P < 0.001). In contrast, 77 patients (2.5%) were diagnosed with AHF, which in the vast majority of cases (77.9%) developed in patients without a history of HF. Arrhythmias during hospital admission and CHF were the main predictors of AHF. Patients developing AHF had significantly higher mortality (46.8% vs. 19.7%; P < 0.001). Finally, the withdrawal of beta-blockers, mineralocorticoid receptor antagonists and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated with a significant increase in in-hospital mortality. CONCLUSIONS: Patients with COVID-19 have a significant incidence of AHF, which is associated with very high mortality rates. Moreover, patients with a history of CHF are prone to developing acute decompensation after a COVID-19 diagnosis. The withdrawal of GDMT was associated with higher mortality.
- Published
- 2020
- Full Text
- View/download PDF
6. Differentiation of ventricular and supraventricular tachycardias based on the analysis of the first postpacing interval after sequential anti-tachycardia pacing in implantable cardioverter-defibrillator patients.
- Author
-
Arenal, Angel, Ortiz, Mercedes, Peinado, Rafael, Merino, Jose L., Quesada, Aurelio, Atienza, Felipe, Alberola, Arcadio García, Ormaetxe, Jose, Castellanos, Eduardo, Rodriguez, Juan C., Pérez, Nicasio, García, Javier, Boluda, Luis, del Prado, Mario, Artés, Antonio, Alberola, Arcadio García, Pérez, Nicasio, García, Javier, and Artés, Antonio
- Subjects
TACHYCARDIA ,DEFIBRILLATORS ,CARDIOLOGY ,HEART ,ANALYSIS of variance ,CARDIAC pacing ,DIFFERENTIAL diagnosis ,DISCRIMINANT analysis ,ELECTROCARDIOGRAPHY ,EXERCISE tests ,EXPERIMENTAL design ,IMPLANTABLE cardioverter-defibrillators ,LONGITUDINAL method ,LOGISTIC regression analysis ,VENTRICULAR tachycardia ,TREATMENT effectiveness ,PREDICTIVE tests ,SUPRAVENTRICULAR tachycardia ,THERAPEUTICS - Abstract
Background: Current discrimination algorithms do not completely avoid inappropriate tachycardia detection.Objectives: This study analyzes the discrimination capability of the changes of the first postpacing interval (FPPI) after successive bursts of anti-tachycardia pacing (ATP) trains in implantable cardioverter-defibrillator (ICD)-recorded tachycardias.Methods: We included 50 ICD patients in this prospective study. We hypothesized that the FPPI variability (FPPIV) when comparing bursts with different numbers of beats would be shorter in ventricular tachycardias (VTs) compared with supraventricular tachycardias (SVTs). The ATP (5-10 pulses, 91% of tachycardia cycle length) was programmed for tachycardias >240 ms.Results: Anti-tachycardia pacing was delivered during 37 sinus tachycardias (STs) in an exercise test, 96 induced VTs in an electrophysiological study, and 198 spontaneous episodes (144 VTs and 54 SVTs). The FPPI remained stable after all ATP bursts in VT but changed continuously in SVT; when comparing bursts of 5 and 10 pulses, the FPPIV was shorter in VT (34 +/- 65 vs.138 +/- 69, P<.0001, in all T and 12 +/- 20 vs. 138 +/- 69, P<.0001, in T>or=320 ms) than in SVT. In T>or=320 ms an FPPIVConclusions: Analysis of FPPIV after ATP discriminates ICD-detected T. Successive bursts (of ATP) trains at 91% of tachycardia cycle length are safe, despite being delivered before rhythm classification. [ABSTRACT FROM AUTHOR] - Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.